Table 4 Studies investigating tissue angiogenic and angiostatic parameters in experimental models of pulmonary fibrosis
From: Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander?
Investigator (year) | Model | Studied Parameters | Summary | Limitations |
|---|---|---|---|---|
Keane et al. 61(1999) | BPF | MIP-2 | Increased levels of MIP-2 in BPF mice / Inhibition of angiogenesis and fibrosis with neutralizing Abs | Model not representative of IPF |
Keane et al. 62(1999) | BPF | CXCL10 | Decreased CXCL10 levels / CXCL10 administration reduced BPF and angiogenic response | Model not representative of IPF |
Jiang et al. 65 (2004) | BPF | CXCR3 | Regulation of BPF by CXCR3 | Model not representative of IPF / Incomplete analysis of angiogenic network |
Tager et al. 78 (2004) | BPF | CXCL10 | Inhibition of BPF by CXCL10 | Model not representative of IPF / Incomplete analysis of angiogenic network |
Burdick et al. 63 (2005) | BPF | CXCL11 | Systemic administration of CXCL11 inhibited BPF by altering aberrant vascular remodeling | Model not representative of IPF / Incomplete analysis of angiogenic network |
Belperio et al. 52 (2005) | Murine BOS | CXCL1, 2, 3 CXCR2, VEGF | Increased CXCR2/CXCR2 ligands' levels / Unchanged levels of VEGF / Neutralization of CXCR2 attenuated angiogenesis and BOS | Model has heterotopic positioning and discounts influence of adjacent airway mucosa |
Hamada et al. 64 (2005) | BPF | VEGF, sflt-1 | Anti-VEGF gene therapy attenuates lung injury and fibrosis in BPF mice | Model not representative of IPF / Incomplete analysis of angiogenic network |